CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
P/S ratio for CEL-SCI Corporation (CVM)
P/S ratio as of 2023: 0.00
According to CEL-SCI Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for CEL-SCI Corporation from 1986 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 838.93 |
| 2019 | 602.26 |
| 2018 | 152.01 |
| 2017 | 189.81 |
| 2016 | 130.17 |
| 2015 | 75.33 |
| 2014 | 203051.05 |
| 2013 | 322559.56 |
| 2012 | 345.10 |
| 2011 | 79.59 |
| 2010 | 849.02 |
| 2009 | 2867.67 |
| 2008 | 9244.68 |
| 2007 | 1074.72 |
| 2006 | 390.27 |
| 2005 | 126.59 |
| 2004 | 117.81 |
| 2003 | 148.90 |
| 2002 | 13.44 |
| 2001 | 84.11 |
| 2000 | 107.79 |
| 1999 | 97.32 |
| 1998 | 298.71 |
| 1997 | 170.38 |
| 1996 | 105.75 |
| 1995 | 202.67 |
| 1994 | 262.50 |
| 1993 | 55.00 |
| 1992 | 146.09 |
| 1991 | 487.50 |
| 1990 | 375.00 |
| 1989 | 103.13 |
| 1988 | 195.00 |
| 1987 | 531.25 |
| 1986 | 1039.12 |